Dogwood Therapeutics Inc. (DWTX)
11.50
-1.85 (-13.86%)
At close: Jan 24, 2025, 3:59 PM
10.64
-7.48%
After-hours Jan 24, 2025, 05:56 PM EST
undefined% (undefined)
| Bid | 10.64 |
| Market Cap | 15.32M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -6.32 |
| PE Ratio (ttm) | -1.82 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 11.04 |
| Volume | 8,019,206 |
| Avg. Volume (20D) | 2,182,428 |
| Open | 17.49 |
| Previous Close | 13.35 |
| Day's Range | 10.10 - 19.33 |
| 52-Week Range | 1.62 - 29.28 |
| Beta | undefined |
About DWTX
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, att...
Industry Biotechnology
Sector Healthcare
IPO Date n/a
Employees 4
Stock Exchange NASDAQ
Ticker Symbol DWTX
Website https://www.dwtx.com
4 days ago
+68.45%
Dogwood Therapeutics shares are trading higher aft...
Unlock content with
Pro Subscription
2 months ago
-37.71%
Dogwood Therapeutics shares are trading lower. The company announced top line data from the recently completed BHC IMC-2 Long-COVID study.